Breaking News Instant updates and real-time market news.

VRX

Ticker changed BHC

$15.44

-0.35 (-2.22%)

07:05
04/09/18
04/09
07:05
04/09/18
07:05

Ortho Dermatologics: JAAD publishes results of Phase trials of DUOBRII

Ortho Dermatologics, a division of Valeant Pharmaceuticals, announced that the Journal of the American Academy of Dermatology published for the first time positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of DUOBRIITM lotion in the treatment of plaque psoriasis.2 Studies 1 and 2, which enrolled a total of 418 patients, showed DUOBRII was consistently more effective than vehicle in achieving treatment success (defined as those with at least a two-grade improvement from baseline in an Investigator Global Assessment score, and 'clear' or 'almost clear' skin), demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2). At week eight, 35.8% (Study 1) and 45.3% (Study 2) had achieved the primary efficacy outcome, compared to 7% and 12.5% on vehicle. The majority of patients maintained treatment success over the four-week post treatment period. DUOBRII was also superior in reducing psoriasis signs and symptoms and body surface area affected compared to vehicle. In addition, DUOBRII showed significant reductions in the severity of the clinical signs of psoriasis. The most common treatment-related adverse events were contact dermatitis (6.3%), application site pain (2.6%) and pruritus (2.2%).

  • 08

    May

  • 13

    May

  • 18

    Jun

  • 27

    Aug

VRX Ticker changed BHC
$15.44

-0.35 (-2.22%)

03/21/18
DBAB
03/21/18
NO CHANGE
Target $20
DBAB
Buy
Deutsche Bank continues to like risk/reward for Valeant shares
Valeant Pharmaceuticals could get more credit for its dermatology pipeline over time as it discloses more details on assets, secures approvals, and executes on launches, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He notes that one key difference between Valeant's longer-term outlook and his model is sales potential for the dermatology business. Management believes it can double sales from 2018-2022 to greater than $1B while Gilbert's estimates are much lower at $600M, likely due to lower pipeline contribution. He believes success in dermatology would represent "significant upside" to his current price target of $20. The analyst continues to like the risk/reward for the stock and maintains a Buy rating on Valeant.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Valeant upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Valeant to Neutral and raised its price target to $15 from $10. Koffler sees a lack of near-term sell catalysts and views 2018 guidance as achievable.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Mizuho upgrades Valeant to Neutral on lack of negative catalysts
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals to Neutral from Underperform and raised her price target for the shares to $15 from $10. The drugmaker closed yesterday at $15.79. The analyst, while remaining concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." Further, she views the company's 2018 guidance as achievable.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

16:19
11/15/18
11/15
16:19
11/15/18
16:19
Hot Stocks
Williams-Sonoma announces partnership with Reliance Brands for India market »

Williams-Sonoma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

16:18
11/15/18
11/15
16:18
11/15/18
16:18
Earnings
Williams-Sonoma backs FY18 EPS view of $4.26-$4.36, consensus $4.34 »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WES

Western Gas Partners

$44.45

-0.13 (-0.29%)

, APC

Anadarko

$55.49

1.09 (2.00%)

16:18
11/15/18
11/15
16:18
11/15/18
16:18
Recommendations
Western Gas Partners, Anadarko analyst commentary  »

Western Gas Partners…

WES

Western Gas Partners

$44.45

-0.13 (-0.29%)

APC

Anadarko

$55.49

1.09 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

QCOM

Qualcomm

$55.38

1.44 (2.67%)

16:18
11/15/18
11/15
16:18
11/15/18
16:18
Downgrade
Qualcomm rating change  »

Qualcomm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCSB

PCSB Financial

$19.72

0.4 (2.07%)

16:17
11/15/18
11/15
16:17
11/15/18
16:17
Hot Stocks
PCSB Financial authorizes stock repurchase program »

PCSB Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

16:17
11/15/18
11/15
16:17
11/15/18
16:17
Earnings
Williams-Sonoma reports Q3 adjusted EPS 95c, consensus 94c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/15/18
11/15
16:17
11/15/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$49.98

1.47 (3.03%)

16:17
11/15/18
11/15
16:17
11/15/18
16:17
Hot Stocks
Mercury Systems awarded multi-year contract from aircraft manufacturer »

Mercury Systems confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$55.49

1.09 (2.00%)

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Hot Stocks
Anadarko sees 2019 total MMBOE 260 - 270 »

Sees 2019 Oil (MBOPD) 410…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBM

Cambrex

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Initiation
Cambrex initiated  »

Cambrex initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$74.33

-0.9 (-1.20%)

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Hot Stocks
Nike raises quarterly dividend 10% to 22c per share »

Nike announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTLT

Catalent

$39.06

1.16 (3.06%)

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Initiation
Catalent initiated  »

Catalent initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGII

Digi International

$11.56

0.38 (3.40%)

16:16
11/15/18
11/15
16:16
11/15/18
16:16
Earnings
Digi International sees FY19 EPS 20c-35c »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

QCOM

Qualcomm

$55.38

1.44 (2.67%)

, AAPL

Apple

$191.42

4.61 (2.47%)

16:15
11/15/18
11/15
16:15
11/15/18
16:15
Upgrade
Qualcomm, Apple rating change  »

Qualcomm upgraded to…

QCOM

Qualcomm

$55.38

1.44 (2.67%)

AAPL

Apple

$191.42

4.61 (2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGII

Digi International

$11.56

0.38 (3.40%)

16:15
11/15/18
11/15
16:15
11/15/18
16:15
Earnings
Digi International sees Q1 EPS (3c)-(1c) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

INWK

InnerWorkings

$4.76

0.01 (0.21%)

16:15
11/15/18
11/15
16:15
11/15/18
16:15
Hot Stocks
InnerWorkings announces multi-year technology contract, terms not stated »

InnerWorkings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/15/18
11/15
16:15
11/15/18
16:15
General news
Breaking General news story  »

Week of 11/5 Money Supply…

16:15
11/15/18
11/15
16:15
11/15/18
16:15
General news
Breaking General news story  »

Week of 11/14 Fed Balance…

NGVC

Natural Grocers

$16.63

0.03 (0.18%)

16:14
11/15/18
11/15
16:14
11/15/18
16:14
Earnings
Natural Grocers sees FY19 EPS 33c-40c, consensus »

Sees FY19 number of new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

APC

Anadarko

$55.45

1.045 (1.92%)

16:14
11/15/18
11/15
16:14
11/15/18
16:14
Hot Stocks
Anadarko announces 2019 capital program of $4.3B-$4.7B »

Highlights include: 70%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGII

Digi International

$11.56

0.38 (3.40%)

16:14
11/15/18
11/15
16:14
11/15/18
16:14
Earnings
Digi International reports Q4 adjusted EPS 8c, consensus 6c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HAYN

Haynes

$31.30

-0.33 (-1.04%)

16:14
11/15/18
11/15
16:14
11/15/18
16:14
Earnings
Haynes sees Q1 revenue lower than Q4 revenue »

Due to the planned outage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NGVC

Natural Grocers

$16.62

0.015 (0.09%)

16:13
11/15/18
11/15
16:13
11/15/18
16:13
Earnings
Natural Grocers reports Q4 EPS 9c vs. 6c a year ago »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

APC

Anadarko

$55.31

0.91 (1.67%)

16:12
11/15/18
11/15
16:12
11/15/18
16:12
Hot Stocks
Anadarko raises share repurchase authorization by $1B, hikes dividend 20% »

Anadarko announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.